GLP-1 RECEPTOR AGONISTS AND RISK OF VENOUS THROMBOEMBOLISM AND PULMONARY EMBOLISM IN TYPE 2 DIABETES: EVIDENCE FROM A LARGE, REAL-WORLD DATABASE ANALYSIS
IRAKLI LEMONJAVA, Nino Gudushauri(Einstein Medical Center Philadelphia), Kevin Bryan Lo(Einstein Medical Center Philadelphia), Jose Manuel Martinez Manzano(Brigham and Women's Hospital), Zurab Azmaiparashvili(Jefferson Hospital), Irakli Tskhakaia(Jefferson Hospital)
Cited by 0
Related Papers
Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association
|Circulation|2023|1.7k
A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association
|Circulation|2023|1.1k
Interstitial Lung Disease in Relatives of Patients with Pulmonary Fibrosis
|American Journal of Respiratory and Critical Care Medicine|2020|105
Single Cell RNA-seq and Mass Cytometry Reveals a Novel and a Targetable Population of Macrophages in Idiopathic Pulmonary Fibrosis
|bioRxiv (Cold Spring Harbor Laboratory)|2021|48
A Tale of Two Proteolytic Machines: Matrix Metalloproteinases and the Ubiquitin–Proteasome System in Pulmonary Fibrosis
|International Journal of Molecular Sciences|2020|22